Sign In
Buy KVUE
$16.83
-0.490 (-2.83%)
At Close: Jun 03, 2026
Kimberly-Clark CEO talks Kenvue acquisition, calls Tylenol brand 'resilient'
06:40pm, Monday, 03'rd Nov 2025
Kimberly-Clark CEO Mike Hsu told CNBC's Jim Cramer that his company's acquisition of Tylenol maker Kenvue will create value for shareholders, even as the the pain reliever is scrutinized by the Trump
Kenvue's legal risks loom over planned acquisition by Kimberly-Clark
05:20pm, Monday, 03'rd Nov 2025
Kimberly-Clark said on Monday it plans to acquire Band-Aid maker Kenvue , even as the latter company faces thousands of lawsuits involving its painkiller Tylenol and talc-based baby powder, raising qu
S&P 500 Gains & Losses Today: Amazon Stock Jumps After OpenAI Deal; Kimberly-Clark Acquires Kenvue
05:15pm, Monday, 03'rd Nov 2025
A linkup with an artificial intelligence player helped power shares of a top cloud-computing services company higher Monday, while an acquisition in the consumer goods space sent the two stocks on div
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kenvue Inc.
04:58pm, Monday, 03'rd Nov 2025
NEW YORK , Nov. 3, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kenvue Inc. (NYSE: KVUE) and its board of directors concerning the proposed acquisition
KVUE stock price: Kenvue soars 19% today, Kimberly-Clark deal offers a win after Trump Tylenol drama
04:01pm, Monday, 03'rd Nov 2025
It's been a tough few weeks for the consumer health company Kenvue, after President Trump publicly spread unproven claims about Tylenol, one of its core subsidiary brands. Today, though, it seems like
Why Tylenol maker stock is popping despite Trump's autism warning
02:36pm, Monday, 03'rd Nov 2025
Kenvue (NYSE: KVUE) shares surged Monday, climbing by double digits as investors cheered news that consumer goods giant Kimberly-Clark (NASDAQ: KMB) plans to acquire the Tylenol maker
KVUE Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Kenvue to Kimberly-Clark
01:30pm, Monday, 03'rd Nov 2025
MONSEY, N.Y., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) to Kimberly-Clark purs
Top Stock Movers Now: Amazon, Kenvue, Kimberly-Clark, Beyond Meat, and More
12:55pm, Monday, 03'rd Nov 2025
Major U.S. equities indexes were mixed Monday afternoon, as tech stocks gained but most other sectors declined. The S&P 500 and Nasdaq rose, while the Dow fell.
Kenvue deal could double Kimberly-Clark stock's multiple: find out more
12:37pm, Monday, 03'rd Nov 2025
Kenvue Inc (NYSE: KVUE) opened about 20% higher this morning after Kimberly-Clark (NYSE: KMB) announced a $40 billion acquisition of the consumer health company. According to its press release, it wil
Kimberly-Clark to buy Tylenol maker Kenvue in massive consumer merger
12:01pm, Monday, 03'rd Nov 2025
The deal would bring Huggies, Kleenex, Band-Aid, Neutrogena, and Tylenol under one roof, creating a consumer staples giant. Transcript: Caroline Woods: Big brands and big money - Kimberly-Clark is buy
Kimberly-Clark Is Buying Tylenol Maker Kenvue for Nearly $49B. Here's What You Need to Know
11:40am, Monday, 03'rd Nov 2025
Kenvue (KVUE) shares skyrocketed in early trading Monday after Kleenex and Cottonelle maker Kimberly-Clark (KMB) said it's buying the Tylenol maker in a $48.7 billion deal.
Kimberly-Clark to acquire Tylenol-maker Kenvue in $48.7B deal
11:37am, Monday, 03'rd Nov 2025
Kimberly-Clark Corp (NYSE:KMB, ETR:KMY) announced it will acquire Kenvue (NYSE:KVUE), the maker of Tylenol and other consumer health products, in a cash and stock transaction valued at approximately $
Why Kimberly-Clark Stock Just Dropped
11:26am, Monday, 03'rd Nov 2025
Kimberly-Clark will buy Kenvue for $48.7 billion. A merged Kimberly-Clark-Kenvue could have $32 billion in annual sales and profits as high as $5.5 billion.
Kimberly-Clark Buying Tylenol Maker Kenvue in $40 Billion Deal
11:18am, Monday, 03'rd Nov 2025
Kimberly-Clark agreed to buy Kenvue in a deal worth roughly $40 billion in a combination that could create a company with $32 billion in revenue and allow it to surpass Unilever to become the second-b
Tylenol Maker Eyes Best Day Ever on Kimberly-Clark Deal
11:17am, Monday, 03'rd Nov 2025
Tylenol maker and former Johnson & Johnson (JNJ) spinoff Kenvue Inc (NYSE:KVUE) is 16.7% higher to trade at $16.74, after Kimberly-Clark Corp (NASDAQ:KMB) agreed to purchase the pharma name for $48.
